← All Iris Parent Holding CORP filings

Iris Parent Holding CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
LIMN
Iris Parent Holding CORP
10-K: Liminatus Pharma Faces Nasdaq Delisting, Reports Wider Losses
Liminatus Pharma, Inc. reported a significant increase in net loss for 2025, raising substantial doubt about its going concern ability, and is non-compliant with multiple Nasdaq listing rules.